Inflammatory cytokines in depression: Neurobiological mechanisms and therapeutic implications

Neuroscience

Volumn 246, Issue , 2013, Pages 199-229

  Felger, J C ^a   Lotrich, F E ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Brain derived neurotrophic factor; Depression; Dopamine; Inflammatory cytokines; Kynurenines; Serotonin

Indexed keywords

A 804598; ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CELECOXIB; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; DOPAMINE; ESCITALOPRAM; FLUOXETINE; GLUTAMIC ACID; GROWTH FACTOR; INFLIXIMAB; KETAMINE; MODAFINIL; MONOAMINE; NEUROPEPTIDE; NEUROTRANSMITTER; NORADRENALIN; NORTRIPTYLINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PURINERGIC P2X RECEPTOR ANTAGONIST; REBOXETINE; RIBAVIRIN; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANHEDONIA; ANXIETY; AUTONOMIC NEUROPATHY; BRAIN; COGNITION; CYTOKINE PRODUCTION; DEPRESSION; DRUG POTENTIATION; FATIGUE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEPATITIS C; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MAJOR DEPRESSION; NEUROBIOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SLEEP;

ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; BRAIN; CYTOKINES; DEPRESSION; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 84878923139     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.04.060     Document Type: Review

References (437)

1. Aan Het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S., Mathew S.J. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010, 67:139-145.
2. Abe S., Hori T., Suzuki T., Baba A., Shiraishi H., Yamamoto T. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res 1999, 24:359-363.
3. Aguilera M., Arias B., Wichers M., Barrantes-Vidal N., Moya J., Villa H., van Os J., Ibanez M., Ruiperez M., Ortet G., Fananas L. Early adversity and 5-HTT/BDNF genes: new evidence of gene-environment interactions on depressive symptoms in a general population. Psychol Med 2009, 39:1425-1432.
4. Akhondzadeh S., Jafari S., Raisi F., Nasehi A.A., Ghoreishi A., Salehi B., Mohebbi-Rasa S., Raznahan M., Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009, 26:607-611.
5. Anderson D.R., Meyers M.J., Vernier W.F., Mahoney M.W., Kurumbail R.G., Caspers N., Poda G.I., Schindler J.F., Reitz D.B., Mourey R.J. Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). J Med Chem 2007, 50:2647-2654.
6. Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 2009, 34:4-20.
7. Arango V., Underwood M.D., Gubbi A.V., Mann J.J. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res 1995, 688:121-133.
8. Arango V., Underwood M.D., Boldrini M., Tamir H., Kassir S.A., Hsiung S., Chen J.J., Mann J.J. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 2001, 25:892-903.
9. Arborelius L., Owens M.J., Plotsky P.M., Nemeroff C.B. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol 1999, 160:1-12.
10. Arrieta M.C., Bistritz L., Meddings J.B. Alterations in intestinal permeability. Gut 2006, 55:1512-1520.
11. Asadullah K., Docke W.D., Sabat R., Volk H.D., Sterry W. The treatment of psoriasis with IL-10: rationale and review of the first clinical trials. Expert Opin Investig Drugs 2000, 9:95-102.
12. Banks W.A., Erickson M.A. The blood-brain barrier and immune function and dysfunction. Neurobiol Dis 2010, 37:26-32.
13. Banks W.A., Kastin A.J., Broadwell R.D. Passage of cytokines across the blood-brain barrier. Neuroimmunomodulation 1995, 2:241-248.
14. Banks W.A., Farr S.A., Morley J.E. Entry of blood-borne cytokines into the central nervous system: effects on cognitive processes. Neuroimmunomodulation 2002, 10:319-327.
15. Behan W.M., McDonald M., Darlington L.G., Stone T.W. Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl. Br J Pharmacol 1999, 128:1754-1760.
16. Bercik P., Denou E., Collins J., Jackson W., Lu J., Jury J., Deng Y., Blennerhassett P., Macri J., McCoy K.D., Verdu E.F., Collins S.M. The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice. Gastroenterology 2011, 141:599-609. 609 e591-593.
17. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S., Krystal J.H. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000, 47:351-354.
18. Bersano A., Aghemo A., Rumi M.G., Ballabio E., Candelise L., Colombo M. Recovery after l-DOPA treatment in peginterferon and ribavirin induced parkinsonism. Eur J Intern Med 2008, 19:370-371.
19. Besedovsky H.O., del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996, 17:64-102.
20. Blasi F., Riccio M., Brogi A., Strazza M., Taddei M.L., Romagnoli S., Luddi A., D'Angelo R., Santi S., Costantino-Ceccarini E., Melli M. Constitutive expression of interleukin-1beta (IL-1beta) in rat oligodendrocytes. Biol Chem 1999, 380:259-264.
21. Blazer D.G., Kessler R.C., McGonagle K.A., Swartz M.S. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994, 151:979-986.
22. Block M.L., Zecca L., Hong J.S. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57-69.
23. Bluthe R.M., Walter V., Parnet P., Laye S., Lestage J., Verrier D., Poole S., Stenning B.E., Kelley K.W., Dantzer R. Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. C R Acad Sci III 1994, 317:499-503.
24. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini M., Almerighi C., Levrero M., Egyed B., Bosmans E., Meltzer H.Y., Maes M. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001, 105:45-55.
25. Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M., Artini M., Almerighi C., Verkerk R., Meltzer H., Maes M. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002, 22:86-90.
26. Borish L.C., Nelson H.S., Lanz M.J., Claussen L., Whitmore J.B., Agosti J.M., Garrison L. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med 1999, 160:1816-1823.
27. Borish L.C., Nelson H.S., Corren J., Bensch G., Busse W.W., Whitmore J.B., Agosti J.M. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107:963-970.
28. Bosker F.J., Hartman C.A., Nolte I.M., Prins B.P., Terpstra P., Posthuma D., van Veen T., Willemsen G., DeRijk R.H., de Geus E.J., Hoogendijk W.J., Sullivan P.F., Penninx B.W., Boomsma D.I., Snieder H., Nolen W.A. Poor replication of candidate genes for major depressive disorder using genome-wide association data. Mol Psychiatry 2011, 16:516-532.
29. Bower J.E., Ganz P.A., Aziz N., Fahey J.L. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002, 64:604-611.
30. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF (2011) Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. PNAS early edition pnas.1102999108.
31. Breder C.D., Dinarello C.A., Saper C.B. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science 1988, 240:321-324.
32. Bryant P.A., Trinder J., Curtis N. Sick and tired: does sleep have a vital role in the immune system?. Nat Rev Immunol 2004, 4:457-467.
33. Brydon L., Harrison N.A., Walker C., Steptoe A., Critchley H.D. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry 2008, 63:1022-1029.
34. Bufalino C., Hepgul N., Aguglia E., Pariante C.M. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain Behav Immun 2012.
35. Bull S.J., Huezo-Diaz P., Binder E.B., Cubells J.F., Ranjith G., Maddoc C., Miyazaki C., Alexander N., Hotopf M., Cleare A.J., Norris S., Cassidy E., Aitchison K.J., Miller A.H., Pariante C.M. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009, 14:1095-1104.
36. Buret A.G. How stress induces intestinal hypersensitivity. Am J Pathol 2006, 168:3-5.
37. Burton B.K., Bausell H., Katz R., Laduca H., Sullivan C. Sapropterin therapy increases stability of blood phenylalanine levels in patients with BH4-responsive phenylketonuria (PKU). Mol Genet Metab 2010, 101:110-114.
38. Butler J.M., Case L.D., Atkins J., Frizzell B., Sanders G., Griffin P., Lesser G., McMullen K., McQuellon R., Naughton M., Rapp S., Stieber V., Shaw E.G. A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys 2007, 69:1496-1501.
39. Cadet J.L., Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 1998, 32:117-131.
40. Calabrese J.R., Skwerer R.G., Barna B., Gulledge A.D., Valenzuela R., Butkus A., Subichin S., Krupp N.E. Depression, immunocompetence, and prostaglandins of the E series. Psychiatry Res 1986, 17:41-47.
41. Candito M., Nagatsu T., Chambon P., Chatel M. High-performance liquid chromatographic measurement of cerebrospinal fluid tetrahydrobiopterin, neopterin, homovanillic acid and 5-hydroxindoleacetic acid in neurological diseases. J Chromatogr B Biomed Appl 1994, 657:61-66.
42. Cao C., Matsumura K., Yamagata K., Watanabe Y. Involvement of cyclooxygenase-2 in LPS-induced fever and regulation of its mRNA by LPS in the rat brain. Am J Physiol 1997, 272:R1712-R1725.
43. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004, 56:819-824.
44. Capuron L., Ravaud A., Dantzer R. Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med 2001, 63:376-386.
45. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
46. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., Miller A.H. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003, 54:906-914.
47. Capuron L., Raison C.L., Musselman D.L., Lawson D.H., Nemeroff C.B., Miller A.H. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003, 160:1342-1345.
48. Capuron L., Ravaud A., Miller A.H., Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004, 18:205-213.
49. Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., Woolwine B., Berns G.S., Nemeroff C.B., Miller A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007, 32:2384-2392.
50. Capuron L., Fornwalt F.B., Knight B.T., Harvey P.D., Ninan P.T., Miller A.H. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?. J Affect Disord 2009, 119:181-185.
51. Capuron L., Schroecksnadel S., Feart C., Aubert A., Higueret D., Barberger-Gateau P., Laye S., Fuchs D. Chronic low-grade inflammation in elderly person is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011, 70:175-182.
52. Capuron L., Schroecksnadel S., Feart C., Aubert A., Higueret D., Barberger-Gateau P., Laye S., Fuchs D. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. Biol Psychiatry 2011, 70:175-182.
53. Capuron L., Pagnoni G., Drake D.F., Woolwine B.J., Spivey J.R., Crowe R.J., Votaw J.R., Goodman M.M., Miller A.H. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry 2012, 69:1044-1053.
54. Carney R.M., Freedland K.E. Treatment-resistant depression and mortality after acute coronary syndrome. Am J Psychiatry 2009, 166:410-417.
55. Caspi A., Sugden K., Moffitt T.E., Taylor A., Craig I.W., Harrington H., McClay J., Mill J., Martin J., Braithwaite A., Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003, 301:386-389.
56. Cassano P., Lattanzi L., Fava M., Navari S., Battistini G., Abelli M., Cassano G.B. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry 2005, 50:357-360.
57. Cassidy E.M., Manning D., Byrne S., Bolger E., Murray F., Sharifi N., Wallace E., Keogan M., O'Keane V. Acute effects of low-dose interferon-alpha on serum cortisol and plasma interleukin-6. J Psychopharmacol 2002, 16:230-234.
58. Cattaneo A., Gennarelli M., Uher R., Breen G., Farmer A., Aitchison K.J., Craig I.W., Anacker C., Zunsztain P.A., McGuffin P., Pariante C.M. Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology 2013, 38:377-385.
59. Charney D.S. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998, 59(Suppl. 14):11-14.
60. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., Borden E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8:237-249.
61. Chen M., Ona V.O., Li M., Ferrante R.J., Fink K.B., Zhu S., Bian J., Guo L., Farrell L.A., Hersch S.M., Hobbs W., Vonsattel J.P., Cha J.H., Friedlander R.M. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000, 6:797-801.
62. Chen P., Jiang T., Ouyang J., Cui Y., Chen Y. Epigenetic programming of diverse glucocorticoid response and inflammatory/immune-mediated disease. Med Hypotheses 2009, 73:657-658.
63. Chen Z., Jalabi W., Shpargel K.B., Farabaugh K.T., Dutta R., Yin X., Kidd G.J., Bergmann C.C., Stohlman S.A., Trapp B.D. Lipopolysaccharide-induced microglial activation and neuroprotection against experimental brain injury is independent of hematogenous TLR4. J Neurosci 2012, 32:11706-11715.
64. Chung I.Y., Benveniste E.N. Tumor necrosis factor-alpha production by astrocytes. Induction by lipopolysaccharide, IFN-gamma, and IL-1 beta. J Immunol 1990, 144:2999-3007.
65. Cirulli F., Reif A., Herterich S., Lesch K.P., Berry A., Francia N., Aloe L., Barr C.S., Suomi S.J., Alleva E. A novel BDNF polymorphism affects plasma protein levels in interaction with early adversity in rhesus macaques. Psychoneuroendocrinology 2011, 36:372-379.
66. Clement H.W., Buschmann J., Rex S., Grote C., Opper C., Gemsa D., Wesemann W. Effects of interferon-gamma, interleukin-1 beta, and tumor necrosis factor-alpha on the serotonin metabolism in the nucleus raphe dorsalis of the rat. J Neural Transm 1997, 104:981-991.
67. Cohen S., Janicki-Deverts D., Doyle W.J., Miller G.E., Frank E., Rabin B.S., Turner R.B. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci USA 2012, 109:5995-5999.
68. Collins J.M., Riccardi R., Trown P., O'Neill D., Poplack D.G. Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: comparison of intravenous, intramuscular, and intraventricular delivery. Cancer Drug Deliv 1985, 2:247-253.
69. Coogan A., O'Neill L.A.J., CO'Connor J.J. The p38 MAP kinase inhibitor SB203580 antagonises the inhibitory effect of interleukin-1b on long-term potentiation in the rat dentate gyrus in vitro. Neuroscience 1999, 93:57-69.
70. Coombes J.L., Powrie F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol 2008, 8:435-446.
71. Cortese G.P., Barrientos R.M., Maier S.F., Patterson S.L. Aging and a peripheral immune challenge interact to reduce mature brain-derived neurotrophic factor and activation of TrkB, PLCgamma1, and ERK in hippocampal synaptoneurosomes. J Neurosci 2011, 31:4274-4279.
72. Cunnington C., Channon K.M. Tetrahydrobiopterin: pleiotropic roles in cardiovascular pathophysiology. Heart 2010, 96:1872-1877.
73. Curran B., O'Connor J.J. The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience 2001, 108:83-90.
74. Danese A., Pariante C.M., Caspi A., Taylor A., Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci USA 2007, 104:1319-1324.
75. Danese A., Moffitt T.E., Pariante C.M., Ambler A., Poulton R., Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry 2008, 65:409-415.
76. Danese A., Caspi A., Williams B., Ambler A., Sugden K., Mika J., Werts H., Freeman J., Pariante C.M., Moffitt T.E., Arseneault L. Biological embedding of stress through inflammation processes in childhood. Mol Psychiatry 2011, 16:244-246.
77. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun 2007, 21:153-160.
78. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56.
79. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
80. De La Garza R.I., Asnis G.M. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res 2003, 977:70-79.
81. de Paiva V.N., Lima S.N., Fernandes M.M., Soncini R., Andrade C.A., Giusti-Paiva A. Prostaglandins mediate depressive-like behaviour induced by endotoxin in mice. Behav Brain Res 2010, 215:146-151.
82. Di Pucchio T., Danese S., De Cristofaro R., Rutella S. Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds. Expert Opin Ther Pat 2010, 20:229-250.
83. D'Mello C., Le T., Swain M.G. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factoralpha signaling during peripheral organ inflammation. J Neurosci 2009, 29:2089-2102.
84. Dong M., Giles W.H., Felitti V.J., Dube S.R., Williams J.E., Chapman D.P., Anda R.F. Insights into causal pathways for ischemic heart disease: adverse childhood experiences study. Circulation 2004, 110:1761-1766.
85. Donnelly-Roberts D.L., Namovic M.T., Surber B., Vaidyanathan S.X., Perez-Medrano A., Wang Y., Carroll W.A., Jarvis M.F. [3H]A-804598 ([3H]2-cyano-1-[(1S)-1-phenylethyl]-3-quinolin-5-ylguanidine) is a novel, potent, and selective antagonist radioligand for P2X7 receptors. Neuropharmacology 2009, 56:223-229.
86. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctot K.L. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010, 67:446-457.
87. Drachmann B.J., Bock C., Vinberg M., Werg eT, Gether U, Vedel Kessing L Interaction between genetic polymorphisms and stressful life events in first episode depression. Journal of Affective Disorders 2009, 119:107-115.
88. Dufton N., Hannon R., Brancaleone V., Dalli J., Patel H.B., Gray M., D'Acquisto F., Buckingham J.C., Perretti M., Flower R.J. Anti-inflammatory role of the murine formyl-peptide receptor 2: ligand-specific effects on leukocyte responses and experimental inflammation. J Immunol 2010, 184:2611-2619.
89. Duman R.S., Monteggia L.M. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006, 59:1116-1127.
90. Duman C.H., Schlesinger L., Kodama M., Russel D.S., Duman R.S. A role for MAP kinase signaling in behavioral models of depression and antidepressant treatment. Biol Psychiatry 2007, 61:661-670.
91. Dumitrescu C., Biondi R., Xia Y., Cardounel A.J., Druhan L.J., Ambrosio G., Zweier J.L. Myocardial ischemia results in tetrahydrobiopterin (BH4) oxidation with impaired endothelial function ameliorated by BH4. Proc Natl Acad Sci USA 2007, 104:15081-15086.
92. Dunlop B.W., Nemeroff C.B. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007, 64:327-337.
93. Dunn A.J. Cytokine activation of the HPA axis. Ann N Y Acad Sci 2000, 917:608-617.
94. Dunn A.J., Swiergiel A.H. The role of cytokines in infection-related behavior. Ann N Y Acad Sci 1998, 840:577-585.
95. Dunn A.J., Wang J., Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 1999, 461:117-127.
96. Dunn A.J., Swiergiel A.H., de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies?. Neurosci Biobehav Rev 2005, 29:891-909.
97. Dybala M., Maciag D., Cichy A., Pomierny-Chamiolo L., Partyka A., Librowski T., Nowak G. Medium supplementation with zinc enables detection of imipramine-induced adaptation in glycine/NMDA receptors labeled with [3H]L-689,560. Source Pharmacol Rep 2006, 58:753-757.
98. Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., Chaly T., Robeson W., Margouleff D., Przedborski S., et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 1994, 14:783-801.
99. Eisenberger N.I., Berkman E.T., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010, 68:748-754.
100. Elmquist J.K., Breder C.D., Sherin J.E., Scammell T.E., Hickey W.F., Dewitt D., Saper C.B. Intravenous lipopolysaccharide induces cyclooxygenase 2-like immunoreactivity in rat brain perivascular microglia and meningeal macrophages. J Comp Neurol 1997, 381:119-129.
101. Epstein J., Pan H., Kocsis J.H., Yang Y., Butler T., Chusid J., Hochberg H., Murrough J., Strohmayer E., Stern E., Silbersweig D.A. Lack of ventral striatal response to positive stimuli in depressed versus normal subjects. Am J Psychiatry 2006, 163:1784-1790.
102. Ericsson A., Kovacs K.J., Sawchenko P.E. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J Neurosci 1994, 14:897-913.
103. Evans D.L., Staab J.P., Petitto J.M., Morrison M.F., Szuba M.P., Ward H.E., Wingate B., Luber M.P., O'Reardon J.P. Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999, 60(Suppl. 4):40-55. (discussion 56).
104. Fabry Z., Fitzsimmons K.M., Herlein J.A., Moninger T.O., Dobbs M.B., Hart M.N. Production of the cytokines interleukin 1 and 6 by murine brain microvessel endothelium and smooth muscle pericytes. J Neuroimmunol 1993, 47:23-34.
105. Fagarasan S., Kawamoto S., Kanagawa O., Suzuki K. Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. Annu Rev Immunol 2010, 28:243-273.
106. Fahey B., Hickey B., Kelleher D., O'Dwyer A.M., O'Mara S.M. The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats. Behav Brain Res 2007, 182:80-87.
107. Fava M., Borus J.S., Alpert J.E., Nierenberg A.A., Rosenbaum J.F., Bottiglieri T. Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997, 154:426-428.
108. Felger J.C., Miller A.H. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol 2012, 33:315-327.
109. Felger J.C., Alagbe O., Hu F., Mook D., Freeman A.A., Sanchez M.M., Kalin N.H., Ratti E., Nemeroff C.B., Miller A.H. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry 2007, 62:1324-1333.
110. Felger J.C., Alagbe O., Pace T.W., Woolwine B.J., Hu F., Raison C.L., Miller A.H. Early activation of p38 mitogen activated protein kinase is associated with interferon-alpha-induced depression and fatigue. Brain Behav Immun 2011, 25:1094-1098.
111. Felger J.C., Cole S.W., Pace T.W., Hu F., Woolwine B.J., Doho G.H., Raison C.L., Miller A.H. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-alpha treatment: relationship with depression and fatigue. Psychol Med 2012, 42:1591-1603.
112. Felger J.C., Li L., Marvar P.J., Woolwine B.J., Harrison D.G., Raison C.L., Miller A.H. Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun 2012.
113. Felitti V.J., Anda R.F., Nordenberg D., Williamson D.F., Spitz A.M., Edwards V., Koss M.P., Marks J.S. Relationship of childhood abuse and household dysfunction to many of the leading causes of death in adults. The Adverse Childhood Experiences (ACE) Study. Am J Prev Med 1998, 14:245-258.
114. Ferrari D., Wesselborg S., Bauer M.K., Schulze-Osthoff K. Extracellular ATP activates transcription factor NF-kappaB through the P2Z purinoreceptor by selectively targeting NF-kappaB p65. J Cell Biol 1997, 139:1635-1643.
115. Ferrari D., Pizzirani C., Adinolfi E., Lemoli R.M., Curti A., Idzko M., Panther E., Di Virgilio F. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006, 176:3877-3883.
116. Ferris M.J., Mactutus C.F., Booze R.M. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev 2008, 32:883-909.
117. Fitzgerald P., O'Brien S.M., Scully P., Rijkers K., Scott L.V., Dinan T.G. Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 2006, 36:37-43.
118. Fleshner M. Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome. Brain Behav Immun 2013, 27:1-7.
119. Foley D.L., Neale M.C., Gardner C.O., Pickles A., Prescott C.A., Kendler K.S. Major depression and associated impairment: same or different genetic and environmental risk factors?. Am J Psychiatry 2003, 160:2128-2133.
120. Frenois F., Moreau M., O'Connor J., Lawson M., Micon C., Lestage J., Kelley K.W., Dantzer R., Castanon N. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 2007, 32:516-531.
121. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci 1997, 247:228-233.
122. Fujigaki H., Saito K., Fujigaki S., Takemura M., Sudo K., Ishiguro H., Seishima M. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J Biochem 2006, 139:655-662.
123. Fukui S., Schwarcz R., Rapoport S.I., Takada Y., Smith Q.R. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 1991, 56:2007-2017.
124. Furman D.J., Hamilton J.P., Gotlib I.H. Frontostriatal functional connectivity in major depressive disorder. Biol Mood Anxiety Disord 2011, 1:11.
125. Galvao-de Almeida A., Quarantini L.C., Sampaio A.S., Lyra A.C., Parise C.L., Parana R., de Oliveira I.R., Koenen K.C., Miranda-Scippa A., Guindalini C. Lack of association of indoleamine 2,3-dioxygenase polymorphisms with interferon-alpha-related depression in hepatitis C. Brain Behav Immun 2011, 25:1491-1497.
126. Gao H.M., Hong J.S., Zhang W., Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002, 22:782-790.
127. Gelman B.B., Spencer J.A., Holzer C.E., Soukup V.M. Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol 2006, 1:410-420.
128. Gertsik L., Poland R.E., Bresee C., Rapaport M.H. Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol 2012, 32:61-64.
129. Gilbody S., Lewis S., Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol 2007, 165:1-13.
130. Gilbody S., Lightfoot T., Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Community Health 2007, 61:631-637.
131. Ginsberg L.D., Oubre A.Y., Daoud Y.A. L-Methylfolate plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode. Innov Clin Neurosci 2011, 8:19-28.
132. Gochee P.A., Powell E.E., Purdie D.M., Pandeya N., Kelemen L., Shorthouse C., Jonsson J.R., Kelly B. Association between apolipoprotein E epsilon4 and neuropsychiatric symptoms during interferon alpha treatment for chronic hepatitis C. Psychosomatics 2004, 45:49-57.
133. Godbout J.P., Berg B.M., Krzyszton C., Johnson R.W. Alpha-tocopherol attenuates NFkappaB activation and pro-inflammatory cytokine production in brain and improves recovery from lipopolysaccharide-induced sickness behavior. J Neuroimmunol 2005, 169:97-105.
134. Godfrey P.S., Toone B.K., Carney M.W., Flynn T.G., Bottiglieri T., Laundy M., Chanarin I., Reynolds E.H. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990, 336:392-395.
135. Goshen I., Yirmiya R. Interleukin-1 (IL-1): a central regulator of stress responses. Front Neuroendocrinol 2009, 30:30-45.
136. Goshen I., Yirmiya R. The role of pro-inflammatory cytokines in memory processes and neural plasticity. Psychoneuroimmunology, 4E 2007, Elsevier, Inc. R. Ader (Ed.).
137. Greenberg D.B., Gray J.L., Mannix C.M., Eisenthal S., Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage 1993, 8:196-200.
138. Greig N.H., Soncrant T.T., Wozniak K.M., Rapoport S.I. Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration. J Pharmacol Exp Ther 1988, 245:574-580.
139. Guan Z., Fang J. Peripheral immune activation by lipopolysaccharide decreases neurotrophins in the cortex and hippocampus in rats. Brain Behav Immun 2006, 20:64-71.
140. Gudmundsson P., Skoog I., Waern M., Blennow K., Palsson S., Rosengren L., Gustafson D. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. Am J Geriatr Psychiatry 2007, 15:832-838.
141. Guidetti P., Schwarcz R. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?. Adv Exp Med Biol 2003, 527:137-145.
142. Guillemin G.J., Smith D.G., Smythe G.A., Armati P.J., Brew B.J. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv Exp Med Biol 2003, 527:105-112.
143. Guillemin G.J., Brew B.J., Noonan C.E., Takikawa O., Cullen K.M. Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol 2005, 31:395-404.
144. Guillemin G.J., Meininger V., Brew B.J. Implications for the kynurenine pathway and quinolinic acid in amyotrophic lateral sclerosis. Neurodegener Dis 2005, 2:166-176.
145. Guillemin G.J., Smythe G., Takikawa O., Brew B.J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 2005, 49:15-23.
146. Guillemin G.J., Wang L., Brew B.J. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation 2005, 2:16.
147. Guillot T.S., Miller G.W. Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol Neurobiol 2009, 39:149-170.
148. Guo J.Y., Li C.Y., Ruan Y.P., Sun M., Qi X.L., Zhao B.S., Luo F. Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain. Eur J Pharmacol 2009, 612:54-60.
149. Haeffel G.J., Getchell M., Koposov R.A., Yrigollen C.M., Deyoung C.G., Klinteberg B.A., Oreland L., Ruchkin V.V., Grigorenko E.L. Association between polymorphisms in the dopamine transporter gene and depression: evidence for a gene-environment interaction in a sample of juvenile detainees. Psychol Sci 2008, 19:62-69.
150. Hardingham G.E., Fukunaga Y., Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002, 5:405-414.
151. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
152. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Critchley H.D. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009, 66:407-414.
153. Harrison N.A., Brydon L., Walker C., Gray M.A., Steptoe A., Dolan R.J., Critchley H.D. Neural origins of human sickness in interoceptive responses to inflammation. Biol Psychiatry 2009, 66:415-422.
154. Hashimoto R., Nagatsu T., Ohta T., Mizutani M., Omura I. Changes in the concentrations of tetrahydrobiopterin, the cofactor of tyrosine hydroxylase, in blood under physical stress and in depression. Ann N Y Acad Sci 2004, 1018:378-386.
155. Hashimoto K., Sawa A., Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007, 62:1310-1316.
156. Hayley S., Poulter M., Merali Z., Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005, 135:659-678.
157. Heim C., Owens M.J., Plotsky P.M., Nemeroff C.B. Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and post-traumatic stress disorder. Psychopharmacol Bull 1997, 33:185-192.
158. Heim C., Newport D.J., Mletzko T., Miller A.H., Nemeroff C.B. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology 2008, 33:693-710.
159. Henderson N.D., Turri M.G., DeFries J.C., Flint J. QTL analysis of multiple behavioral measures of anxiety in mice. Behav. Genet. 2004, 34:267-293.
160. Heyes M.P., Saito K., Crowley J.S., Davis L.E., Demitrack M.A., Der M., Dilling L.A., Elia J., Kruesi M.J., Lackner A., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992, 115(Pt 5):1249-1273.
161. Hill M.N., Gorzalka B.B. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord: Drug Targets 2009, 8:451-458.
162. Hong S., Gronert K., Devchand P.R., Moussignac R.L., Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003, 278:14677-14687.
163. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
164. Huang L., Baban B., Johnson B.A., Mellor A.L. Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol 2010, 29:133-155.
165. Ida T., Hara M., Nakamura Y., Kozaki S., Tsunoda S., Ihara H. Cytokine-induced enhancement of calcium-dependent glutamate release from astrocytes mediated by nitric oxide. Neurosci Lett 2008, 432:232-236.
166. Iwata M., Ota K.T., Duman R.S. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 2012.
167. Jang K.L., Livesley W.J., Taylor S., Stein M.B., Moon E.C. Heritability of individual depressive symptoms. J Affect Disord 2004, 80:125-133.
168. Jazayeri S., Keshavarz S.A., Tehrani-Doost M., Djalali M., Hosseini M., Amini H., Chamari M., Djazayery A. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res 2010, 178:112-115.
169. Jehn C.F., Kuehnhardt D., Bartholomae A., Pfeiffer S., Krebs M., Regierer A.C., Schmid P., Possinger K., Flath B.C. Biomarkers of depression in cancer patients. Cancer 2006, 107:2723-2729.
170. Kaasinen V., Nurmi E., Bruck A., Eskola O., Bergman J., Solin O., Rinne J.O. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 2001, 124:1125-1130.
171. Kamata M., Higuchi H., Yoshimoto M., Yoshida K., Shimizu T. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 2000, 10:129-132.
172. Kaneko N., Kudo K., Mabuchi T., Takemoto K., Fujimaki K., Wati H., Iguchi H., Tezuka H., Kanba S. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006, 31:2619-2626.
173. Kanellopoulos D., Gunning F.M., Morimoto S.S., Hoptman M.J., Murphy C.F., Kelly R.E., Glatt C., Lim K.O., Alexopoulos G.S. Hippocampal volumes and the brain-derived neurotrophic factor val66met polymorphism in geriatric major depression. Am J Geriatr Psychiatry 2011, 19:13-22.
174. Karg K., Burmeister M., Shedden K., Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch Gen Psychiatry 2011, 68:444-454.
175. Karimi K., Inman M.D., Bienenstock J., Forsythe P. Lactobacillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Crit Care Med 2009, 179:186-193.
176. Katsuura G., Arimura A., Koves K., Gottschall P.E. Involvement of organum vasculosum of lamina terminalis and preoptic area in interleukin 1 beta-induced ACTH release. Am J Physiol 1990, 258:E163-E171.
177. Kaufman J., Yang B.Z., Douglas-Palumberi H., Grasso D., Lipschitz D., Houshyar S., Krystal J.H., Gelernter J. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry 2006, 59:673-680.
178. Kazumori H., Ishihara S., Rumi M.A., Ortega-Cava C.F., Kadowaki Y., Kinoshita Y. Transforming growth factor-alpha directly augments histidine decarboxylase and vesicular monoamine transporter 2 production in rat enterochromaffin-like cells. Am J Physiol Gastrointest Liver Physiol 2004, 286:G508-G514.
179. Kendler K.S., Thornton L.M., Gardner C.O. Genetic risk, number of previous depressive episodes, and stressful life events in predicting onset of major depression. Am J Psychiatry 2001, 158:582-586.
180. Kenis G., Prickaerts J., van Os J., Koek G.H., Robaeys G., Steinbusch H.W.M., Wichers M. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?. Int J Neuropsychopharmacol 2010, 14:247-253.
181. Kessler R.C., Chiu W.T., Demler O., Merikangas K.R., Walters E.E. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005, 62:617-627.
182. Khaodhiar L., Ling P.R., Blackburn G.L., Bistrian B.R. Serum levels of interleukin-6 and C-reactive protein correlate with body mass index across the broad range of obesity. JPEN J Parenter Enteral Nutr 2004, 28:410-415.
183. Kim S.U., de Vellis J. Microglia in health and disease. J Neurosci Res 2005, 81:302-313.
184. Kim B., Jeong H.K., Kim J.H., Lee S.Y., Jou I., Joe E.H. Uridine 5'-diphosphate induces chemokine expression in microglia and astrocytes through activation of the P2Y6 receptor. J Immunol 2011, 186:3701-3709.
185. Kitagami T., Yamada K., Miura H., Hashimoto R., Nabeshima T., Ohta T. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res 2003, 978:104-114.
186. Konsman J.P., Parnet P., Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002, 25:154-159.
187. Konsman J.P., Vigues S., Mackerlova L., Bristow A., Blomqvist A. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol 2004, 472:113-129.
188. Koo J.W., Duman R.S. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 2008, 105:751-756.
189. Koo J.W., Russo S.J., Ferguson D., Nestler E.J., Duman R.S. Nuclear factor-kappaB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci USA 2010, 107:2669-2674.
190. Koo J.W., Russo S.J., Ferguson D., Nestler N.J., Duman R.S. Nuclear factor-kb is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc Natl Acad Sci U.. 2010, 107:2669-2674.
191. Kraus M.R., Al-Taie O., Schafer A., Pfersdorff M., Lesch K.P., Scheurlen M. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007, 132:1279-1286.
192. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318.
193. Kruijshaar M.E., Barendregt J., Vos T., de Graaf R., Spijker J., Andrews G. Lifetime prevalence estimates of major depression: an indirect estimation method and a quantification of recall bias. Eur J Epidemiol 2005, 20:103-111.
194. Krupp L.B., Coyle P.K., Doscher C., Miller A., Cross A.H., Jandorf L., Halper J., Johnson B., Morgante L., Grimson R. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995, 45:1956-1961.
195. Kumai T., Tateishi T., Tanaka M., Watanabe M., Shimizu H., Kobayashi S. Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci 2000, 67:663-669.
196. Kumakura Y., Cumming P. PET studies of cerebral levodopa metabolism: a review of clinical findings and modeling approaches. Neuroscientist 2009, 15:635-650.
197. Kumar S., Boehm J., Lee J.C. P38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003, 2:717-726.
198. Kunugi H., Hori H., Adachi N., Numakawa T. Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin Neurosci 2010, 64:447-459.
199. Lacroix S., Rivest S. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem 1998, 70:452-466.
200. Lalancette-Hebert M., Julien C., Cordeau P., Bohacek I., Weng Y.C., Calon F., Kriz J. Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage. Stroke 2011, 42:2903-2909.
201. Lanquillon S., Krieg J.C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000, 22:370-379.
202. LaVoie M.J., Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 1999, 19:1484-1491.
203. Lee Y.K., Mazmanian S.K. Has the microbiota played a critical role in the evolution of the adaptive immune system?. Science 2010, 330:1768-1773.
204. Leenders K.L., Palmer A.J., Quinn N., Clark J.C., Firnau G., Garnett E.S., Nahmias C., Jones T., Marsden C.D. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986, 49:853-860.
205. Lestage J., Verrier D., Palin K., Dantzer R. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun 2002, 16:596-601.
206. Levine J., Barak Y., Chengappa K.N., Rapoport A., Rebey M., Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999, 40:171-176.
207. Lieb J., Karmali R., Horrobin D. Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins Leukot Med 1983, 10:361-367.
208. Lieberman A.P., Pitha P.M., Shin H.S., Shin M.L. Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci USA 1989, 86:6348-6352.
209. Lim W., Hong S., Nelesen R., Dimsdale J.E. The association of obesity, cytokine levels, and depressive symptoms with diverse measures of fatigue in healthy subjects. Arch Intern Med 2005, 165:910-915.
210. Lin P.Y., Su K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007, 68:1056-1061.
211. Lindqvist D., Janelidze S., Hagell P., Erhardt S., Samuelsson M., Minthon L., Hansson O., Bjorkqvist M., Traskman-Bendz L., Brundin L. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009, 66:287-292.
212. Linnoila M., Whorton A.R., Rubinow D.R., Cowdry R.W., Ninan P.T., Waters R.N. CSF prostaglandin levels in depressed and schizophrenic patients. Arch Gen Psychiatry 1983, 40:405-406.
213. Liu Y., Samuel C.E. Editing of glutamate receptor subunit B pre-mRNA by splice-site variants of interferon-inducible double-stranded RNA-specific adenosine deaminase ADAR1. J Biol Chem 1999, 274:5070-5077.
214. Liu Z., Zhu F., Wang G., Xiao Z., Tang J., Liu W., Wang H., Liu H., Wang X., Wu Y., Cao Z., Li W. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 2007, 414:155-158.
215. Loberiza F.R., Rizzo J.D., Bredeson C.N., Antin J.H., Horowitz M.M., Weeks J.C., Lee S.J. Association of depressive syndrome and early deaths among patients after stem-cell transplantation for malignant diseases. J Clin Oncol 2002, 20:2118-2126.
216. Loftis J.M., Hauser P. The phenomenology and treatment of interferon-induced depression. J Affect Disord 2004, 82:175-190.
217. Loftis J.M., Hauser P., Macey T.A., Lowe J.D. Can rodents be used to model interferon-alpha-induced depressive symptoms?. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:1364-1365. author reply 1366.
218. Loftis J.M., Wall J.M., Pagel R.L., Hauser P. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats. Psychoneuroendocrinology 2006, 31:1289-1294.
219. Loftis J.M., Patterson A.L., Wilhelm C.J., McNett H., Morasco B.J., Huckans M., Morgan T., Saperstein S., Asghar A., Hauser P. Vulnerability to somatic symptoms of depression during interferon-alpha therapy for hepatitis C: a 16-week prospective study. J Psychosom Res 2013, 74:57-63.
220. Lopresti A.L., Hood S.D., Drummond P.D. Multiple antidepressant potential modes of action of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects. J Psychopharmacol 2012, 26:1512-1524.
221. Lotrich F.E. Major depression during interferon-alpha treatment: vulnerability and prevention. Dialogues Clin Neurosci 2009, 11:417-425.
222. Lotrich F. Management of psychiatric disease in hepatitis C treatment candidates. Curr Hepat Rep 2010, 9:113-118.
223. Lotrich F.E. Gene-environment interactions in geriatric depression. Psychiatr Clin North Am 2011, 34:357-376. viii.
224. Lotrich F. Inflammatory cytokines, growth factors, and depression. Curr Pharm Des 2012, 18:5920-5935.
225. Lotrich F.E., Pollock B.G., Kirshner M., Ferrell R.F., Reynolds C.F. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 2008, 33:123-130.
226. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism. Biol Psychiatry 2009, 65:344-348.
227. Lotrich F.E., Ferrell R.E., Rabinovitz M., Pollock B.G. Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha. Clin Neuropharmacol 2010, 33:191-197.
228. Lotrich F.E., Loftis J.M., Ferrell R.E., Rabinovitz M., Hauser P. IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy. J Interferon Cytokine Res 2011, 31:331-336.
229. Lotrich F.E., Sears B., McNamara R.K. Elevated ratio of arachidonic acid to long-chain omega-3 fatty acids predicts depression development following interferon-alpha treatment: Relationship with interleukin-6. Brain Behav Immun 2012.
230. Lotrich F.E., Albusaysi S., Ferrell R.E. Brain-derived neurotrophic factor serum levels and genotype: association with depression during interferon-alpha treatment. Neuropsychopharmacology 2013, 38:985-995.
231. Lu X., Ma L., Ruan L., Kong Y., Mou H., Zhang Z., Wang Z., Wang J.M., Le Y. Resveratrol differentially modulates inflammatory responses of microglia and astrocytes. J Neuroinflammation 2010, 7:46.
232. Lu D.Y., Leung Y.M., Su K.P. Interferon-alpha induces nitric oxide synthase expression and haem oxygenase-1 down-regulation in microglia: implications of cellular mechanism of IFN-alpha-induced depression. Int J Neuropsychopharmacol 2012, 1-12.
233. Lucae S., Salyakina D., Barden N., Harvey M., Gagne B., Labbe M., Binder E.B., Uhr M., Paez-Pereda M., Sillaber I., Ising M., Bruckl T., Lieb R., Holsboer F., Muller-Myhsok B. P2RX7, a gene coding for a purinergic ligand-gated ion channel, is associated with major depressive disorder. Hum Mol Genet 2006, 15:2438-2445.
234. Ma D., Forsythe P., Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis factor alph-induced interleukin-8 expression. Infect Immun 2004, 72:5308-5314.
235. Maddock C., Landau S., Barry K., Maulayah P., Hotopf M., Cleare A.J., Norris S., Pariante C.M. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 2005, 10:332-333.
236. Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999, 461:25-46.
237. Maes M., Lambrechts J., Bosmans E., Jacobs J., Suy E., Vandervorst C., de Jonckheere C., Minner B., Raus J. Evidence for a systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychol Med 1992, 22:45-53.
238. Maes M., Bosmans E., Meltzer H.Y., Scharpe S., Suy E. Interleukin-1 beta: a putative mediator of HPA axis hyperactivity in major depression?. Am J Psychiatry 1993, 150:1189-1193.
239. Maes M., Galecki P., Verkerk R., Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 2011, 32:264-273.
240. Maier S.F., Watkins L.R. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998, 105:83-107.
241. Majer M., Welberg L.A., Capuron L., Pagnoni G., Raison C.L., Miller A.H. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav Immun 2008, 22:870-880.
242. Malison R.T., Price L.H., Berman R., van Dyck C.H., Pelton G.H., Carpenter L., Sanacora G., Owens M.J., Nemeroff C.B., Rajeevan N., Baldwin R.M., Seibyl J.P., Innis R.B., Charney D.S. Reduced brain serotonin transporter availability in major depression as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry 1998, 44:1090-1098.
243. Manki H., Kanba S., Muramatsu T., Higuchi S., Suzuki E., Matsushita S., Ono Y., Chiba H., Shintani F., Nakamura M., Yagi G., Asai M. Dopamine D2, D3 and D4 receptor and transporter gene polymorphisms and mood disorders. J Affect Disord 1996, 40:7-13.
244. Mann J.J., Huang Y.Y., Underwood M.D., Kassir S.A., Oppenheim S., Kelly T.M., Dwork A.J., Arango V. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000, 57:729-738.
245. Mar Fan H.G., Clemons M., Xu W., Chemerynsky I., Breunis H., Braganza S., Tannock I.F. A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer. Support Care Cancer 2008, 16:577-583.
246. Martinez J.M., Garakani A., Yehuda R., Gorman J.M. Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress Anxiety 2012, 29:32-38.
247. Masand P.S., Gupta S. Selective serotonin-reuptake inhibitors: an update. Harv Rev Psychiatry 1999, 7:69-84.
248. Masilamoni G.J., Bogenpohl J.W., Alagille D., Delevich K., Tamagnan G., Votaw J.R., Wichmann T., Smith Y. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain 2011, 134:2057-2073.
249. Maslanik T., Mahaffey L., Tannura K., Beninson L., Greenwood B.N., Fleshner M. The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure. Brain Behav Immun 2013, 28:54-62.
250. Massie M.J. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004, 57-71.
251. Matsumura K., Kobayashi S. Signaling the brain in inflammation: the role of endothelial cells. Front Biosci 2004, 9:2819-2826.
252. Matute C. Glutamate and ATP signalling in white matter pathology. J Anat 2011, 219:53-64.
253. Matute C., Domercq M., Sanchez-Gomez M.V. Glutamate-mediated glial injury: mechanisms and clinical importance. Glia 2006, 53:212-224.
254. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5:45.
255. McKinney W.T., Eising R.G., Moran E.C., Suomi S.J., Harlow H.F. Effects of reserpine on the social behavior of rhesus monkeys. Dis Nerv Syst 1971, 32:735-741.
256. McNally L., Bhagwagar Z., Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008, 13:501-510.
257. McNamara R.K., Lotrich F.E. Elevated immune-inflammatory signaling in mood disorders: a new therapeutic target?. Expert Rev Neurother 2012, 12:1143-1161.
258. McNutt M.D., Liu S., Manatunga A., Royster E.B., Raison C.L., Woolwine B.J., Demetrashvili M.F., Miller A.H., Musselman D.L. Neurobehavioral effects of interferon-alpha in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology 2012, 37:1444-1454.
259. Mehler M.F., Kessler J.A. Hematolymphopoietic and inflammatory cytokines in neural development. Trends Neurosci 1997, 20:357-365.
260. Meier-Ewert H.K., Ridker P.M., Rifai N., Regan M.M., Price N.J., Dinges D.F., Mullington J.M. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol 2004, 43:678-683.
261. Meisner F., Scheller C., Kneitz S., Sopper S., Neuen-Jacob E., Riederer P., ter Meulen V., Koutsilieri E. Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine. Neuropsychopharmacology 2008, 33:2228-2236.
262. Mendall M.A., Patel P., Asante M., Ballam L., Morris J., Strachan D.P., Camm A.J., Northfield T.C. Relation of serum cytokine concentrations to cardiovascular risk factors and coronary heart disease. Heart 1997, 78:273-277.
263. Mendlewicz J., Kriwin P., Oswald P., Souery D., Alboni S., Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006, 21:227-231.
264. Mentis M.J., McIntosh A.R., Perrine K., Dhawan V., Berlin B., Feigin A., Edwards C., Mattis P., Eidelberg D. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson's disease. Am J Psychiatry 2002, 159:746-754.
265. Miller D.W. Immunobiology of the blood-brain barrier. J Neurovirol 1999, 5:570-578.
266. Miller A.L. The methylation, neurotransmitter, and antioxidant connections between folate and depression. Altern Med Rev 2008, 13:216-226.
267. Miller G.E., Cole S.W. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol Psychiatry 2012, 72:34-40.
268. Miller G.E., Cohen S., Ritchey A.K. Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model. Health Psychol 2002, 21:531-541.
269. Miller G.E., Stetler C.A., Carney R.M., Freedland K.E., Banks W.A. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002, 90:1279-1283.
270. Miller G.E., Freedland K.E., Carney R.M., Stetler C.A., Banks W.A. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun 2003, 17:276-285.
271. Miller G.E., Rohleder N., Stetler C., Kirschbaum C. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom Med 2005, 67:679-687.
272. Miller A.H., Ancoli-Israel S., Bower J.E., Capuron L., Irwin M.R. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008, 26:971-982.
273. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65:732-741.
274. Mizoi Y., Kaneko H., Oharazawa A., Kuroiwa H. Parkinsonism in a patient receiving interferon alpha therapy for chronic hepatitis C. Rinsho Shinkeigaku 1997, 37:54-56.
275. Molendijk M.L., Bus B.A., Spinhoven P., Penninx B.W., Kenis G., Prickaerts J., Voshaar R.C., Elzinga B.M. Serum levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011, 16:1088-1095.
276. Molina-Hernandez M., Tellez-Alcantara N.P., Perez-Garcia J., Olivera-Lopez J.I., Jaramillo-Jaimes M.T. Antidepressant-like actions of minocycline combined with several glutamate antagonists. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:380-386.
277. Monk J.P., Phillips G., Waite R., Kuhn J., Schaaf L.J., Otterson G.A., Guttridge D., Rhoades C., Shah M., Criswell T., Caligiuri M.A., Villalona-Calero M.A. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006, 24:1852-1859.
278. Moraska A.R., Sood A., Dakhil S.R., Sloan J.A., Barton D., Atherton P.J., Suh J.J., Griffin P.C., Johnson D.B., Ali A., Silberstein P.T., Duane S.F., Loprinzi C.L. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 2010, 28:3673-3679.
279. Morikawa O., Sakai N., Obara H., Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998, 349:317-324.
280. Moron J.A., Zakharova I., Ferrer J.V., Merrill G.A., Hope B., Lafer E.M., Lin Z.C., Wang J.B., Javitch J.A., Galli A., Shippenberg T.S. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci 2003, 23:8480-8488.
281. Morrow G.R., Hickok J.T., Roscoe J.A., Raubertas R.F., Andrews P.L., Flynn P.J., Hynes H.E., Banerjee T.K., Kirshner J.J., King D.K. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. J Clin Oncol 2003, 21:4635-4641.
282. Mossner R., Heils A., Stober G., Okladnova O., Daniel S., Lesch K.P. Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int 1998, 33:251-254.
283. Motivala S.J., Sarfatti A., Olmos L., Irwin M.R. Inflammatory markers and sleep disturbance in major depression. Psychosom Med 2005, 67:187-194.
284. Muller N., Schwarz M.J., Dehning S., Douhe A., Cerovecki A., Goldstein-Muller B., Spellmann I., Hetzel G., Maino K., Kleindienst N., Moller H.J., Arolt V., Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684.
285. Muskin P.R. Major depressive disorder and other medical illness: a two-way street. Ann Clin Psychiatry 2010, 22:S15-S20.
286. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry 1998, 55:580-592.
287. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Greiner K., Nemeroff C.B., Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
288. Musselman D.L., Miller A.H., Porter M.R., Manatunga A., Gao F., Penna S., Pearce B.D., Landry J., Glover S., McDaniel J.S., Nemeroff C.B. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry 2001, 158:1252-1257.
289. Nadjar A., Bluthe R.M., May M.J., Dantzer R., Parnet P. Inactivation of the cerebral NFkappaB pathway inhibits interleukin-1beta-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology 2005, 30:1492-1499.
290. Nanni V., Uher R., Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry 2012, 169:141-151.
291. Nemeroff C.B., Heim C.M., Thase M.E., Klein D.N., Rush A.J., Schatzberg A.F., Ninan P.T., McCullough J.P., Weiss P.M., Dunner D.L., Rothbaum B.O., Kornstein S., Keitner G., Keller M.B. Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci USA 2003, 100:14293-14296.
292. Neurauter G., Grahmann A.V., Klieber M., Zeimet A., Ledochowski M., Sperner-Unterweger B., Fuchs D. Serum phenylalanine concentrations in patients with ovarian carcinoma correlate with concentrations of immune activation markers and of isoprostane-8. Cancer Lett 2008, 272:141-147.
293. Neurauter G., Schrocksnadel K., Scholl-Burgi S., Sperner-Unterweger B., Schubert C., Ledochowski M., Fuchs D. Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab 2008, 9:622-627.
294. Nichol C.A., Lee C.L., Edelstein M.P., Chao J.Y., Duch D.S. Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. Proc Natl Acad Sci USA 1983, 80:1546-1550.
295. Nierenberg A.A., Husain M.M., Trivedi M.H., Fava M., Warden D., Wisniewski S.R., Miyahara S., Rush A.J. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010, 40:41-50.
296. Nishino S., Ueno R., Ohishi K., Sakai T., Hayaishi O. Salivary prostaglandin concentrations: possible state indicators for major depression. Am J Psychiatry 1989, 146:365-368.
297. O'Connor J.C., Lawson M.A., Andre C., Briley E.M., Szegedi S.S., Lestage J., Castanon N., Herkenham M., Dantzer R., Kelley K.W. Induction of IDO by bacille Calmette-Guerin is responsible for development of murine depressive-like behavior. J Immunol 2009, 182:3202-3212.
298. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009, 14:511-522.
299. O'Connor J.C., Lawson M.A., Andre C., Moreau M., Lestage J., Castanon N., Kelley K.W., Dantzer R. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatry 2009, 14:511-522.
300. Ohishi K., Ueno R., Nishino S., Sakai T., Hayaishi O. Increased level of salivary prostaglandins in patients with major depression. Biol Psychiatry 1988, 23:326-334.
301. Opp M.R., Born J., Irwin M.R. Sleep and the immune system. Psychoneuroimmunology 2007, 570-618. Academic Press, New York, NY. R. Ader (Ed.).
302. Oxenkrug G., Perianayagam M., Mikolich D., Requintina P., Shick L., Ruthazer R., Zucker D., Summergrad P. Interferon-gamma (+874) T/A genotypes and risk of IFN-alpha-induced depression. J Neural Transm 2011, 118:271-274.
303. Pace T.W., Mletzko T.C., Alagbe O., Musselman D.L., Nemeroff C.B., Miller A.H., Heim C.M. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry 2006, 163:1630-1633.
304. Pace T.W., Hu F., Miller A.H. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun 2007, 21:9-19.
305. Pae C.U., Marks D.M., Han C., Patkar A.A. Does minocycline have an antidepressant effect?. Biomed Pharmacother 2008, 62:308-311.
306. Palma J.P., Kwon D., Clipstone N.A., Kim B.S. Infection with Theiler's murine encephalomyelitis virus directly induces proinflammatory cytokines in primary astrocytes via NF-kappaB activation: potential role for the initiation of demyelinating disease. J Virol 2003, 77:6322-6331.
307. Pan W., Kastin A.J. Interactions of cytokines with the blood-brain barrier: implications for feeding. Curr Pharm Des 2003, 9:827-831.
308. Papakostas G.I., Petersen T., Mischoulon D., Green C.H., Nierenberg A.A., Bottiglieri T., Rosenbaum J.F., Alpert J.E., Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry 2004, 65:1096-1098.
309. Papakostas G.I., Petersen T., Mischoulon D., Ryan J.L., Nierenberg A.A., Bottiglieri T., Rosenbaum J.F., Alpert J.E., Fava M. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry 2004, 65:1090-1095.
310. Papakostas G.I., Mischoulon D., Shyu I., Alpert J.E., Fava M. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Am J Psychiatry 2010, 167:942-948.
311. Pariante C.M., Lightman S.L. The HPA axis in major depression: classical theories and new developments. Trends Neurosci 2008, 31:464-468.
312. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001, 49:391-404.
313. Pariante C.M., Pearce B.D., Pisell T.L., Sanchez C.I., Po C., Su C., Miller A.H. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology 1999, 140:4359-4366.
314. Park H.S., Park J.Y., Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005, 69:29-35.
315. Patel H.C., Boutin H., Allan S.M. Interleukin-1 in the brain: mechanisms of action in acute neurodegeneration. Ann N Y Acad Sci 2003, 992:39-47.
316. Payne B., Hateley C., Ong E., Premchand N., Schmid M., Schwab U., Newton J., Price D. HIV-associated fatigue in the era of highly active antiretroviral therapy: novel biological mechanisms?. HIV Med 2013, 14:247-251.
317. Pemberton L.A., Kerr S.J., Smythe G., Brew B.J. Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res 1997, 17:589-595.
318. Peng C.H., Chiou S.H., Chen S.J., Chou Y.C., Ky H.H., Cheng C.K. Neuroprotection by imipramine against lipopolysaccharide-induced apoptosis in hippocampus-dreived neural stem cellsmediated by activation of BDNF and the MAPK pathway. Eur Neuropsychopharmacol 2008, 18:128-140.
319. Perez-De La Cruz V., Carrillo-Mora P., Santamaria A. Quinolinic acid, an endogenous molecule combining excitotoxicity, oxidative stress and other toxic mechanisms. Int J Tryptophan Res 2012, 5:1-8.
320. Perry E.K., Marshall E.F., Blessed G., Tomlinson B.E., Perry R.H. Decreased imipramine binding in the brains of patients with depressive illness. Br J Psychiatry 1983, 142:188-192.
321. Pierucci-Lagha A., Covault J., Bonkovsky H.L., Feinn R., Abreu C., Sterling R.K., Fontana R.J., Kranzler H.R. HALT-C Trial Group. A functional serotonin transporter gene polymorphism and depressive effects associated with interferon-alpha treatment. Psychosomatics 2010, 51:137-148.
322. Plane J.M., Shen Y., Pleasure D.E., Deng W. Prospects for minocycline neuroprotection. Arch Neurol 2010, 67:1442-1448.
323. Pollak Y., Yirmiya R. Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment. Int J Neuropsychopharmacol 2002, 5:389-399.
324. Porcelli S., Fabbri C., Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol 2012, 22:239-258.
325. Possel H., Noack H., Putzke J., Wolf G., Sies H. Selective upregulation of inducible nitric oxide synthase (iNOS) by lipopolysaccharide (LPS) and cytokines in microglia: in vitro and in vivo studies. Glia 2000, 32:51-59.
326. Prasad A.S. Impact of the discovery of human zinc deficiency on health. J Am Coll Nutr 2009, 28:257-265.
327. Prather A.A., Rabinovitz M., Pollock B.G., Lotrich F.E. Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality. Brain Behav Immun 2009, 23:1109-1116.
328. Pregelj P., Nedic G., Paska A.V., Zupanc T., Nikolac M., Balazic J., Tomori M., Komel R., Seler D.M., Pivac N. The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide. J Affect Disord 2011, 128:287-290.
329. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009, 66:522-526.
330. Pucci E., Branas P., D'Amico R., Giuliani G., Solari A., Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev 2007, CD002818.
331. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 2004, 279:1415-1421.
332. Raison C.L., Miller A.H. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry 2003, 54:283-294.
333. Raison C.L., Miller A.H. Is depression an inflammatory disorder?. Curr Psychiatry Rep 2011, 13:467-475.
334. Raison C.L., Miller A.H. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry 2013, 18:15-37.
335. Raison C.L., Borisov A.S., Broadwell S.D., Capuron L., Woolwine B.J., Jacobson I.M., Nemeroff C.B., Miller A.H. Depression during pegylated interferon-alpha plus ribavirin therapy: prevalence and prediction. J Clin Psychiatry 2005, 66:41-48.
336. Raison C.L., Demetrashvili M., Capuron L., Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123.
337. Raison C.L., Woolwine B.J., Demetrashvili M.F., Borisov A.S., Weinreib R., Staab J.P., Zajecka J.M., Bruno C.J., Henderson M.A., Reinus J.F., Evans D.L., Asnis G.M., Miller A.H. Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Aliment Pharmacol Ther 2007, 25:1163-1174.
338. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry 2009, 65:296-303.
339. Raison C.L., Borisov A.S., Woolwine B.J., Massung B., Vogt G., Miller A.H. Interferon-alpha effects on diurnal hypothalamic-pituitary-adrenal axis activity: relationship with proinflammatory cytokines and behavior. Mol Psychiatry 2010, 15:535-547.
340. Raison C.L., Dantzer R., Kelley K.W., Lawson M.A., Woolwine B.J., Vogt G., Spivey J.R., Saito K., Miller A.H. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol Psychiatry 2010, 15:393-403.
341. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F., Haroon E., Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. Arch Gen Psychiatry 2012, 1-11.
342. Rammohan K.W., Rosenberg J.H., Lynn D.J., Blumenfeld A.M., Pollak C.P., Nagaraja H.N. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002, 72:179-183.
343. Ramwell P.W., Foegh M., Loeb R., Leovey E.M. Synthesis and metabolism of prostaglandins, prostacyclin, and thromboxanes: the arachidonic acid cascade. Semin Perinatol 1980, 4:3-13.
344. Ressler K.J., Mayberg H.S. Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 2007, 10:1116-1124.
345. Rhee S.H., Pothoulakis C., Mayer E.A. Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 2009, 6:306-314.
346. Riddle E.L., Fleckenstein A.E., Hanson G.R. Mechanisms of methamphetamine-induced dopaminergic neurotoxicity. AAPS J 2006, 8:E413-E418.
347. Ries M., Pritschet K., Schmidt B. Blocking type I interferon production: a new therapeutic option to reduce the HIV-1-induced immune activation. Clin Dev Immunol 2012, 2012:534929.
348. Rios C., Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res 1991, 16:1139-1143.
349. Riteau N., Gasse P., Fauconnier L., Gombault A., Couegnat M., Fick L., Kanellopoulos J., Quesniaux V.F., Marchand-Adam S., Crestani B., Ryffel B., Couillin I. Extracellular ATP is a danger signal activating P2X7 receptor in lung inflammation and fibrosis. Am J Respir Crit Care Med 2010, 182:774-783.
350. Rohleder N., Miller G.E. Acute deviations from long-term trait depressive symptoms predict systemic inflammatory activity. Brain Behav Immun 2008, 22:709-716.
351. Rojas P.S., Fritsch R., Rojas R.A., Jara P., Fiedler J.L. Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients: a pilot study. Psychiatry Res 2011, 189:239-245.
352. Rosenzweig-Lipson S., Hesterberg P., Bergman J. Observational studies of dopamine D1 and D2 agonists in squirrel monkeys. Psychopharmacology 1994, 116:9-18.
353. Rottenberg D.A., Sidtis J.J., Strother S.C., Schaper K.A., Anderson J.R., Nelson M.J., Price R.W. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 1996, 37:1133-1141.
354. Roy A., Linnoila M., Karoum F., Pickar D. Relative activity of metabolic pathways for norepinephrine in endogenous depression. Acta Psychiatr Scand 1986, 73:624-628.
355. Roy A., Evers S.E., Avison W.R., Campbell M.K. Higher zinc intake buffers the impact of stress on depressive symptoms in pregnancy. Nutr Res 2010, 30:695-704.
356. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., Niederehe G., Thase M.E., Lavori P.W., Lebowitz B.D., McGrath P.J., Rosenbaum J.F., Sackeim H.A., Kupfer D.J., Luther J., Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
357. Rytka J.M., Wueest S., Schoenle E.J., Konrad D. The portal theory supported by venous drainage-selective fat transplantation. Diabetes 2011, 60:56-63.
358. Sakai K., Hasegawa C., Okura M., Morikawa O., Ueyama T., Shirai Y., Sakai N., Saito N. Novel variants of murine serotonin transporter mRNA and the promoter activity of its upstream site. Neurosci Lett 2003, 342:175-178.
359. Salazar A., Gonzalez-Rivera B.L., Redus L., Parrott J.M., O'Connor J.C. Indoleamine 2,3-dioxygenase mediates anhedonia and anxiety-like behaviors caused by peripheral lipopolysaccharide immune challenge. Horm Behav 2012, 62:202-209.
360. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
361. Sanchez M.M., Alagbe O., Felger J.C., Zhang J., Graff A.E., Grand A.P., Maestripieri D., Miller A.H. Activated p38 MAPK is associated with decreased CSF 5-HIAA and increased maternal rejection during infancy in rhesus monkeys. Mol Psychiatry 2007, 12:895-897.
362. Sarasombath P., Sumida K., Kaku D.A. Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia. Hawaii Med J 2002, 61(48):57.
363. Sarchiapone M., Carli V., Roy A., Iacoviello L., Cuomo C., Latella M., di Giannantonio M., Janiri L., de Gaetano M., Janal M. Association of polymorphism (Val66Met) of brain-derived neurotrophic factor with suicide attempts in depressed patients. Neuropsychobiology 2008, 57:139-145.
364. Sato T., Suzuki E., Yokoyama M., Semba J., Watanabe S., Miyaoka H. Chronic intraperitoneal injection of interferon-alpha reduces serotonin levels in various regions of rat brain, but does not change levels of serotonin transporter mRNA, nitrite or nitrate. Psychiatry Clin Neurosci 2006, 60:499-506.
365. Schlaak J.F., Trippler M., Hoyo-Becerra C., Erim Y., Kis B., Wang B., Scherbaum N., Gerken G. Selective hyper-responsiveness of the interferon system in major depressive disorders and depression induced by interferon therapy. PLoS One 2012, 7:e38668.
366. Schobitz B., Voorhuis D.A., De Kloet E.R. Localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Neurosci Lett 1992, 136:189-192.
367. Schwarcz R., Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 2002, 303:1-10.
368. Sekirov I., Russell S.L., Antunes L.C., Finlay B.B. Gut microbiota in health and disease. Physiol Rev 2010, 90:859-904.
369. Serhan C.N. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?. Am J Pathol 2010, 177:1576-1591.
370. Shaftel S.S., Carlson T.J., Olschowka J.A., Kyrkanides S., Matousek S.B., O'Banion M.K. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci 2007, 27:9301-9309.
371. Shah A.J., Veledar E., Hong Y., Bremner J.D., Vaccarino V. Depression and history of attempted suicide as risk factors for heart disease mortality in young individuals. Arch Gen Psychiatry 2011, 68:1135-1142.
372. Shimizu H., Ohtani K., Sato N., Nagamine T., Mori M. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-alpha administration. Endocr J 1995, 42:551-556.
373. Shuto H., Kataoka Y., Horikawa T., Fujihara N., Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 1997, 747:348-351.
374. Sissolak G., Hoffbrand A.V., Mehta A.B., Ganeshaguru K. Effects of interferon-alpha (IFN) on the expression of interleukin 1-beta (IL-1), interleukin 6 (IL-6), granulocyte-macrophage colony-stimulating factor (GM-CSF) and tumor necrosis factor-alpha (TNF) in acute myeloid leukemia (AML) blasts. Leukemia 1992, 6:1155-1160.
375. Skaper S.D., Debetto P., Giusti P. P2X(7) receptors in neurological and cardiovascular disorders. Cardiovasc Psychiatry Neurol 2009, 2009:861324.
376. Sluzewska A. Indicators of immune activation in depressed patients. Adv Exp Med Biol 1999, 461:59-73.
377. Sluzewska A., Sobieska M., Rybakowski J.K. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 1997, 35:123-127.
378. Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry 1998, 3:508-511.
379. Smith Q.R., Momma S., Aoyagi M., Rapoport S.I. Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem 1987, 49:1651-1658.
380. Smith A.K., Simon J.S., Gustafson E.L., Noviello S., Cubells J.F., Epstein M.P., Devlin D.J., Qiu P., Albrecht J.K., Brass C.A., Sulkowski M.S., McHutchinson J.G., Miller A.H. Association of a polymorphism in the indoleamine-2,3-dioxygenase gene and interferon-alpha-induced depression in patients with chronic hepatitis C. Mol Psychiatry 2012, 17:781-789.
381. Song C., Merali Z., Anisman H. Variations of nucleus accumbens dopamine and serotonin following systemic interfleukin-1, interleukin-2, or interleukin-6 treatment. Neuroscience 1999, 88:823-836.
382. Spetsieris P.G., Moeller J.R., Dhawan V., Ishikawa T., Eidelberg D. Visualizing the evolution of abnormal metabolic networks in the brain using PET. Comput Med Imaging Graph 1995, 19:295-306.
383. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., Boeing H., Pfeiffer A.F. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817.
384. Sriram K., Miller D.B., O'Callaghan J.P. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha. J Neurochem 2006, 96:706-718.
385. Stahl S.M. Novel therapeutics for depression: l-methylfolate as a trimonoamine modulator and antidepressant-augmenting agent. CNS Spectr 2007, 12:739-744.
386. Stankoff B., Waubant E., Confavreux C., Edan G., Debouverie M., Rumbach L., Moreau T., Pelletier J., Lubetzki C., Clanet M. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005, 64:1139-1143.
387. Stein D.J. Depression, anhedonia, and psychomotor symptoms: the role of dopaminergic neurocircuitry. CNS Spectr 2008, 13:561-565.
388. Steiner J., Bielau H., Brisch R., Danos P., Ullrich O., Mawrin C., Bernstein H.G., Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008, 42:151-157.
389. Stone T.W. Development and therapeutic potential of kynurenic acid and kynurenine derivatives for neuroprotection. Trends Pharmacol Sci 2000, 21:149-154.
390. Stone T.W. Inhibitors of the kynurenine pathway. Eur J Med Chem 2000, 35:179-186.
391. Su K.P., Huang S.Y., Peng C.Y., Lai H.C., Huang C.L., Chen Y.C., Aitchison K.J., Pariante C.M. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. Biol Psychiatry 2010, 67:550-557.
392. Su N., Zhang L., Fei F., Hu H., Wang K., Hui H., Jiang X.F., Li X., Zhen H.N., Li J., Cao B.P., Dang W., Qu Y., Zhou F. The brain-derived neurotrophic factor is associated with alcohol dependence-related depression and antidepressant response. Brain Res 2011, 1415.
393. Suarez E.C. Self-reported symptoms of sleep disturbance and inflammation, coagulation, insulin resistance and psychosocial distress: evidence for gender disparity. Brain Behav Immun 2008, 22:960-968.
394. Suganami T., Ogawa Y. Adipose tissue macrophages: their role in adipose tissue remodeling. J Leukoc Biol 2010, 88:33-39.
395. Sugawara Y., Akechi T., Shima Y., Okuyama T., Akizuki N., Nakano T., Uchitomi Y. Efficacy of methylphenidate for fatigue in advanced cancer patients: a preliminary study. Palliat Med 2002, 16:261-263.
396. Sun S., Xia S., Ji Y., Kersten S., Qi L. The ATP-P2X7 signaling axis is dispensable for obesity-associated inflammasome activation in adipose tissue. Diabetes 2012, 61:1471-1478.
397. Targum S.D., Fava M. Fatigue as a residual symptom of depression. Innov Clin Neurosci 2011, 8:40-43.
398. Tavares R.G., Tasca C.I., Santos C.E.S., Alves L.B., Porciuncula L.O., Emanuelli T., Souza D.O. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 2002, 40:621-627.
399. Tavares R.G., Schmidt A.P., Abud J., Tasca C.I., Souza D.O. In vivo quinolinic acid increases synaptosomal glutamate release in rats: reversal by guanosine. Neurochem Res 2005, 30:439-444.
400. Teeling J.L., Cunningham C., Newman T.A., Perry V.H. The effect of non-steroidal anti-inflammatory agents on behavioural changes and cytokine production following systemic inflammation: Implications for a role of COX-1. Brain Behav Immun 2010, 24:409-419.
401. Tilleux S., Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007, 85:2059-2070.
402. Tong L., Balazs R., Soiampornkul R., Thangnipon W., Cotman C.W. Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging 2008, 29:1380-1393.
403. Trefz F.K., Burton B.K., Longo N., Casanova M.M., Gruskin D.J., Dorenbaum A., Kakkis E.D., Crombez E.A., Grange D.K., Harmatz P., Lipson M.H., Milanowski A., Randolph L.M., Vockley J., Whitley C.B., Wolff J.A., Bebchuk J., Christ-Schmidt H., Hennermann J.B. Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study. J Pediatr 2009, 154:700-707.
404. Treisman G., Fishman M., Schwartz J., Hutton H., Lyketsos C. Mood disorders in HIV infection. Depress Anxiety 1998, 7:178-187.
405. Tsao C.W., Lin Y.S., Cheng J.T., Lin C.F., Wu H.T., Wu S.R., Tsai W.H. Interferon-alpha-induced serotonin uptake in Jurkat T cells via mitogen-activated protein kinase and transcriptional regulation of the serotonin transporter. J Psychopharmacol 2008, 22:753-760.
406. Utz J.R., Lorentz C.P., Markowitz D., Rudser K.D., Diethelm-Okita B., Erickson D., Whitley C.B. START, a double blind, placebo-controlled pharmacogenetic test of responsiveness to sapropterin dihydrochloride in phenylketonuria patients. Mol Genet Metab 2012, 105:193-197.
407. van Rossum E.F., Binder E.B., Majer M., Koper J.W., Ising M., Modell S., Salyakina D., Lamberts S.W., Holsboer F. Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 2006, 59:681-688.
408. Vaswani M., Linda F.K., Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:85-102.
409. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Lotsikas A., Zachman K., Kales A., Prolo P., Wong M.L., Licinio J., Gold P.W., Hermida R.C., Mastorakos G., Chrousos G.P. Circadian interleukin-6 secretion and quantity and depth of sleep. J Clin Endocrinol Metab 1999, 84:2603-2607.
410. Vgontzas A.N., Zoumakis E., Bixler E.O., Lin H.M., Follett H., Kales A., Chrousos G.P. Adverse effects of modest sleep restriction on sleepiness, performance, and inflammatory cytokines. J Clin Endocrinol Metab 2004, 89:2119-2126.
411. Walker A.K., Budac D.P., Bisulco S., Lee A.W., Smith R.A., Beenders B., Kelley K.W., Dantzer R. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depressive-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013.
412. Wang J., Campbell I.L., Zhang H. Systemic interferon-alpha regulates interferon-stimulated genes in the central nervous system. Mol Psychiatry 2008, 13:293-301.
413. Wang Y., Liu X., Yu Y., Han Y., Wei J., Collier D., Li T., Ma X. The role of single nucleotide polymorphism of D2 dopamine receptor gene on major depressive disorder and response to antidepressant treatment. Psychiatry Res 2012, 200:1047-1050.
414. Watkins L.R., Wiertelak E.P., Goehler L.E., Mooney-Heiberger K., Martinez J., Furness L., Smith K.P., Maier S.F. Neurocircuitry of illness-induced hyperalgesia. Brain Res 1994, 639:283-299.
415. Watkins L.R., Goehler L.E., Relton J.K., Tartaglia N., Silbert L., Martin D., Maier S.F. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995, 183:27-31.
416. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Investig 2003, 112:1796-1808.
417. Wichers M.C., Kenis G., Koek G.H., Robaeys G., Nicolson N.A., Maes M. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J Psychosom Res 2007, 62:207-214.
418. Wichmann T., DeLong M.R. Oscillations in the basal ganglia. Nature 1999, 400:621-622.
419. Wichmann T., DeLong M.R. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann N Y Acad Sci 2003, 991:199-213.
420. Willeit M., Praschak-Rieder N., Neumeister A., Pirker W., Asenbaum S., Vitouch O., Tauscher J., Hilger E., Stastny J., Brucke T., Kasper S. [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry 2000, 47:482-489.
421. Williams J.W., Mulrow C.D., Chiquette E., Noel P.H., Aguilar C., Cornell J. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000, 132:743-756.
422. Willner P. Dopamine and depression: a review of recent evidence. I. Empirical studies. Brain Res 1983, 287:211-224.
423. Wojna V., Skolasky R.L., Hechavarria R., Mayo R., Selnes O., McArthur J.C., Melendez L.M., Maldonado E., Zorrilla C.D., Garcia H., Kraiselburd E., Nath A. Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol 2006, 12:356-364.
424. Wu H.Q., Rassoulpour A., Schwarcz R. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?. J Neural Transm 2007, 114:33-41.
425. Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011, 25:181-213.
426. Yirmiya R., Weidenfeld J., Pollak Y., Morag M., Morag A., Avitsur R., Barak O., Reichenberg A., Cohen E., Shavit Y., Ovadia H. Cytokines, "depression due to a general medical condition", and antidepressant drugs. Adv Exp Med Biol 1999, 461:283-316.
427. Yirmiya R., Pollak Y., Morag M., Reichenberg A., Barak O., Avitsur R., Shavit Y., Ovadia H., Weidenfeld J., Morag A., Newman M.E., Pollmacher T. Illness, cytokines, and depression. Ann N Y Acad Sci 2000, 917:478-487.
428. Yoshida K., Alagbe O., Wang X., Woolwine B., Thornbury M., Raison C.L., Miller A.H. Promoter polymorphisms of the interferon-alpha receptor gene and development of Interferon-induced depressive symptoms in patients with chronic hepatitis C: preliminary findings. Neuropsychobiology 2005, 52:55-61.
429. Zhang J.-j., Terreni L., De Simoni M.G., Dunn A.J. Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. Neurochem Int 2001, 38:303-308.
430. Zhang L., Fang Y., Zeng Z., Lian Y., Wei J., Zhu H., Jia Y., Zhao X., Xu Y. BDNF gene polymorphisms are associated with Alzheimer's disease-related depression and antidepressant response. J Alzheimers Dis 2011, 26:523-530.
431. Zhao B., Schwartz J.P. Involvement of cytokines in normal CNS development and neurological diseases: recent progress and perspectives. J Neurosci Res 1998, 52:7-16.
432. Zhu C.B., Carneiro A.M., Dostmann W.R., Hewlett W.A., Blakely R.D. P38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem 2005, 280:15649-15658.
433. Zhu C.B., Blakely R.D., Hewlett W.A. The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 2006, 31:2121-2131.
434. Zhu C.B., Lindler K.M., Owens A.W., Daws L.C., Blakely R.D., Hewlett W.A. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010, 35:2510-2520.
435. Zhu C.B., Lindler K.M., Owens A.W., Daws L.C., Blakely R.D., Hewlett W.A. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010, 35:2510-2520.
436. Zifko U.A., Rupp M., Schwarz S., Zipko H.T., Maida E.M. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002, 249:983-987.
437. Zoller H., Schloegl A., Schroecksnadel S., Vogel W., Fuchs D. Interferon-alpha therapy in patients with hepatitis C virus infection increases plasma phenylalanine and the phenylalanine to tyrosine ratio. J Interferon Cytokine Res 2012, 32:216-220.